Create Free Account

By creating account you will get access to hot stocks & personalised emails

Argenica Therapeutics Ltd

Healthcare AU AGN

0.63AUD
-0.015(2.33%)

Last update at 2024-12-30T04:10:00Z

Day Range

0.620.64
LowHigh

52 Week Range

0.470.98
LowHigh

Fundamentals

  • Previous Close 0.65
  • Market Cap82.62M
  • Volume34132
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-
  • Revenue TTM2.60M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM 1.75M
  • Diluted EPS TTM-0.05

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -4.81504M -4.09075M -1.02945M -0.38340M
Minority interest - - - -
Net income -4.81504M -4.09075M -1.02950M -0.38340M
Selling general administrative 2.25M 1.75M 0.79M 0.02M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation - - - -
Ebit -4.87499M -4.09243M -1.02963M -0.65769M
Ebitda -4.81399M -4.08993M -1.02943M -
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -6.56389M -4.08993M -1.02943M -0.38340M
Other operating expenses - 4.35M 1.33M -
Interest expense 0.00105M 0.00082M 0.00002M 0.00000M
Tax provision 0.00000M 0.00000M 0.00005M 0.00000M
Interest income 0.00105M 0.00250M 0.00020M -
Net interest income 0.06M 0.00168M 0.00018M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense - - 0.00005M -
Total revenue 0.06M 0.00250M 0.00020M 0.00025M
Total operating expenses - 4.35M 1.33M -
Cost of revenue - - - -
Total other income expense net 1.75M 0.26M 0.30M -
Discontinued operations - - - -
Net income from continuing ops -4.81504M -4.09075M -1.02950M -
Net income applicable to common shares -4.81504M -4.09075M -1.02950M -0.65726M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 16.38M 9.54M 9.04M 7.27M 0.38M
Intangible assets - 0.00200M 0.00100M 0.00100M 0.00100M
Earning assets - - - - -
Other current assets 0.09M 0.05M - - 0.00010M
Total liab 2.43M 1.87M 0.74M 0.43M 0.36M
Total stockholder equity 13.95M 7.67M 8.31M 6.85M 0.02M
Deferred long term liab - - - - -
Other current liab 1.02M 0.68M 0.06M 0.05M -
Common stock 28.43M 16.62M 13.07M 8.05M 0.40M
Capital stock - 16.62M 13.07M 8.05M -
Retained earnings -15.68605M -10.31870M -5.50366M -1.41290M -0.38340M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M - - - -
Cash 15.91M 9.29M 8.91M 7.14M 0.34M
Cash and equivalents - - - - -
Total current liabilities 2.43M 1.87M 0.74M 0.43M 0.36M
Current deferred revenue - - - - -
Net debt -15.91266M - -8.91446M -7.14419M -
Short term debt - 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - 1.37M 0.75M 0.21M -
Property plant equipment - - - - -
Total current assets 16.38M 9.54M 9.04M 7.27M 0.38M
Long term investments - - - - -
Net tangible assets - 7.67M 8.31M 6.85M 0.02M
Short term investments - 0.05M - - -
Net receivables 0.37M 0.15M 0.07M 0.08M 0.03M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.40M 1.14M 0.67M 0.37M 0.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.21M - 0.75M 0.21M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.00100M 0.00100M 0.00100M 0.00100M -
Capital lease obligations - - - - -
Long term debt total - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.05000M -0.05000M -0.05000M -0.05000M
Change to liabilities 1.12M 0.29M -0.19972M 0.62M
Total cashflows from investing activities -0.05000M -0.05000M -0.05000M -0.05000M
Net borrowings - - - -
Total cash from financing activities 3.73M 5.13M 7.85M 0.69M
Change to operating activities 0.00753M 0.02M 0.00719M 0.00719M
Net income -4.81504M -4.09075M -1.02950M -0.65726M
Change in cash 0.37M 1.77M 6.80M 0.59M
Begin period cash flow 8.91M 7.14M 0.34M -
End period cash flow 9.29M 8.91M 7.14M 0.34M
Total cash from operating activities -3.30032M -3.36167M -1.04641M -0.10083M
Issuance of capital stock 3.73M 5.13M 7.85M -
Depreciation - - - -
Other cashflows from investing activities -0.05000M - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables -0.07276M -0.00067M -0.09260M -0.05944M
Sale purchase of stock 3.73M 5.13M 7.85M 0.40M
Other cashflows from financing activities 0.00001M 0.00001M 0.00012M 0.00012M
Change to netincome 0.46M 0.43M 0.27M 0.27M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.78M 0.00168M 0.00018M 0.00015M
Stock based compensation - - - -
Other non cash items - - - -
Free cash flow -3.30032M -3.36167M -1.04641M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AGN
Argenica Therapeutics Ltd		 -0.015 2.33% 0.63 - - 31.80 5.92 - -7.2841
CSL
CSL Ltd		 0.72 0.26% 283.07 32.16 27.40 9.19 4.89 6.50 20.17
TLX
Telix Pharmaceuticals Ltd		 -0.28 1.12% 24.67 166.27 77.52 12.93 20.73 12.99 113.45
MSB
Mesoblast Ltd		 0.07 2.47% 2.90 - 454.55 496.55 3.81 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.14 1.13% 12.20 12.08 35.21 8.21 4.53 5.53 7.21

Reports Covered

Stock Research & News

View All

Profile

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is headquartered in Nedlands, Australia.

Argenica Therapeutics Ltd

117 Broadway, Nedlands, WA, Australia, 6009

Key Executives

Name Title Year Born
Dr. Liz Dallimore B.Sc., M.B.A., Ph.D. CEO, MD & Director NA
Dr. Samantha South GAICD, MBA, Ph.D. COO & Exec. Director NA
Ms. Emma Waldon CFO & Company Sec. 1976
Prof. Bruno Philip Meloni Chief Scientific Officer NA
Dr. Meghan Thomas Head of Clinical Devel. NA
Ms. Emma Waldon CFO & Company Secretary 1976
Ms. Emma Waldon CFO & Company Secretary 1976
Ms. Emma Waldon CFO & Company Secretary 1976
Ms. Emma Waldon CFO & Company Secretary 1976
Ms. Emma Waldon CFO & Company Secretary 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.